Cardiac multimarker testing in non-obstructive hypertrophic cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10330579" target="_blank" >RIV/00179906:_____/16:10330579 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/16:43875737 RIV/00216208:11150/16:10330579

Výsledek na webu

<a href="http://mmsl.cz/viCMS/soubory/pdf/MMSL_2016_1_5_WWW.pdf" target="_blank" >http://mmsl.cz/viCMS/soubory/pdf/MMSL_2016_1_5_WWW.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cardiac multimarker testing in non-obstructive hypertrophic cardiomyopathy

Popis výsledku v původním jazyce

The natural history of hypertrophic cardiomyopathy (HCM) varies from an asymptomatic and benign clinical course to sudden premature death. Therefore, the new markers are searched with the aim to detect risk patients and improve their prognosis. The aim of this study was to test a cardiac multimarker testing strategy in detection of initial structural changes in patients with nonobstructive hypertrophic cardiomyopathy (HCM). In the group of 47 patients with nonobstructive HCM (58.4 +- 12.4 years, 12 emales) the mean left ventricle mass was 344.8 +- 129.9 g, the mean left ventricle mass index was 171.4 +- 60.2 g.m-2. We observed increased concentration of cardiac markers in peripheral blood: high sensitivity troponin T (hsTnT): median: 9 ng/L (IQR: 5 - 16 ng/L), vs. controls: 7 (5 - 9) ng/L, p 0.03; creatine kinase MB isoenzyme (CK MB): 2 (1.4 - 2.7) μg/L vs. 1.6 (1.1 - 2.2) μg/L, p 0.04; myoglobin 46.4 (33.3 - 65.2) μg/L vs. 35.6 (22.8 - 43.7) μg/L, p 0.001; heart type of fatty acid binding protein (hFABP): 1.8 (1.4 - 3.3) μg/L vs. 1.6 (1.3 - 2.1) μg/L, p 0.05; glycogen phosphorylase BB (GPBB): 3.9 (2.5 - 6.3) μg/L vs. 2.3 (1.9 - 4.2) μg/L, p 0.001. The analysis of the associations of left ventricle mass index and cardiac markers revealed its significant association with hFABP (r = 0.41, 95% CI: 0.07-0.66, p 0.01), CKMB (r = 0.33, 95% CI: 0.11-0.59, p 0.05), and with hsTnT (r = 0.39, 95%CI: 0.12 - 0.62, p 0.008). This study indicates potential clinical use of the multimarker testing in diagnosis and screening of the hypertrophic cardiomyopathy.

Název v anglickém jazyce

Cardiac multimarker testing in non-obstructive hypertrophic cardiomyopathy

Popis výsledku anglicky

The natural history of hypertrophic cardiomyopathy (HCM) varies from an asymptomatic and benign clinical course to sudden premature death. Therefore, the new markers are searched with the aim to detect risk patients and improve their prognosis. The aim of this study was to test a cardiac multimarker testing strategy in detection of initial structural changes in patients with nonobstructive hypertrophic cardiomyopathy (HCM). In the group of 47 patients with nonobstructive HCM (58.4 +- 12.4 years, 12 emales) the mean left ventricle mass was 344.8 +- 129.9 g, the mean left ventricle mass index was 171.4 +- 60.2 g.m-2. We observed increased concentration of cardiac markers in peripheral blood: high sensitivity troponin T (hsTnT): median: 9 ng/L (IQR: 5 - 16 ng/L), vs. controls: 7 (5 - 9) ng/L, p 0.03; creatine kinase MB isoenzyme (CK MB): 2 (1.4 - 2.7) μg/L vs. 1.6 (1.1 - 2.2) μg/L, p 0.04; myoglobin 46.4 (33.3 - 65.2) μg/L vs. 35.6 (22.8 - 43.7) μg/L, p 0.001; heart type of fatty acid binding protein (hFABP): 1.8 (1.4 - 3.3) μg/L vs. 1.6 (1.3 - 2.1) μg/L, p 0.05; glycogen phosphorylase BB (GPBB): 3.9 (2.5 - 6.3) μg/L vs. 2.3 (1.9 - 4.2) μg/L, p 0.001. The analysis of the associations of left ventricle mass index and cardiac markers revealed its significant association with hFABP (r = 0.41, 95% CI: 0.07-0.66, p 0.01), CKMB (r = 0.33, 95% CI: 0.11-0.59, p 0.05), and with hsTnT (r = 0.39, 95%CI: 0.12 - 0.62, p 0.008). This study indicates potential clinical use of the multimarker testing in diagnosis and screening of the hypertrophic cardiomyopathy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13721" target="_blank" >NT13721: Cílená proteomická analýza u hypertrofické kardiomyopatie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vojenské zdravotnické listy

ISSN

0372-7025

e-ISSN

—

Svazek periodika

85

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

31-38

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—